These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 25403555

  • 1. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
    Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A.
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
    [Abstract] [Full Text] [Related]

  • 2. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
    Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [Abstract] [Full Text] [Related]

  • 3. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [Abstract] [Full Text] [Related]

  • 4. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
    Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA.
    Lung Cancer; 2010 Mar; 67(3):311-7. PubMed ID: 19482372
    [Abstract] [Full Text] [Related]

  • 5. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T.
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [Abstract] [Full Text] [Related]

  • 6. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 7. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S, Zahid I, Routledge T, Scarci M.
    Interact Cardiovasc Thorac Surg; 2011 May 20; 12(5):806-11. PubMed ID: 21266493
    [Abstract] [Full Text] [Related]

  • 8. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
    Pilling J, Dartnell JA, Lang-Lazdunski L.
    Thorac Cardiovasc Surg; 2010 Jun 20; 58(4):215-9. PubMed ID: 20514576
    [Abstract] [Full Text] [Related]

  • 9. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
    Marin-Oyaga VA, Salavati A, Houshmand S, Pasha AK, Gharavi M, Saboury B, Basu S, Torigian DA, Alavi A.
    Hell J Nucl Med; 2015 Jun 20; 18(1):11-8. PubMed ID: 25679073
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
    Niccoli Asabella A, Di Palo A, Altini C, Fanelli M, Ferrari C, Lavelli V, Ranieri G, Gadaleta CD, Rubini G.
    Hell J Nucl Med; 2018 Jun 20; 21(3):191-197. PubMed ID: 30411729
    [Abstract] [Full Text] [Related]

  • 11. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ.
    J Nucl Med; 2007 Sep 20; 48(9):1449-58. PubMed ID: 17704250
    [Abstract] [Full Text] [Related]

  • 12. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
    Bille A, Chicklore S, Okiror L, Cook GJ, Spicer J, Landau D, Lang-Lazdunski L.
    Nucl Med Commun; 2013 Nov 20; 34(11):1075-83. PubMed ID: 23963351
    [Abstract] [Full Text] [Related]

  • 13. Histology of the pleural rind at [18F]FDG PET/CT hot and cold spots in mesothelioma patients after talc pleurodesis and neoadjuvant chemotherapy.
    Soltermann A, Opitz I, Burger IA.
    Pathol Res Pract; 2021 Dec 20; 228():153660. PubMed ID: 34749212
    [Abstract] [Full Text] [Related]

  • 14. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, Uematsu K, Sakai H, Goya T, Kanazawa M, Machida K.
    Oncol Rep; 2012 Feb 20; 27(2):333-8. PubMed ID: 22024889
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G, Moretti A, Piciucchi S, Tiseo M, Bersanelli M, Scarlattei M, Scarpi E, Dubini A, Matteucci F, Sanna S.
    Technol Cancer Res Treat; 2012 Apr 20; 11(2):163-7. PubMed ID: 22335410
    [Abstract] [Full Text] [Related]

  • 16. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
    Incerti E, Broggi S, Fodor A, Cuzzocrea M, Samanes Gajate AM, Mapelli P, Fiorino C, Dell'Oca I, Pasetti M, Cattaneo M, Calandrino R, Gianolli L, Di Muzio N, Picchio M.
    Eur J Nucl Med Mol Imaging; 2018 Nov 20; 45(12):2071-2078. PubMed ID: 29876617
    [Abstract] [Full Text] [Related]

  • 17. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
    Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A.
    J Clin Oncol; 2006 Oct 01; 24(28):4587-93. PubMed ID: 17008700
    [Abstract] [Full Text] [Related]

  • 18. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
    Klabatsa A, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski L, Cook GJ.
    Eur J Nucl Med Mol Imaging; 2014 Feb 01; 41(2):276-82. PubMed ID: 24057459
    [Abstract] [Full Text] [Related]

  • 19. The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort study.
    May IJ, Nowak AK, Francis RJ, Ebert MA, Dhaliwal SS.
    J Med Imaging Radiat Oncol; 2024 Feb 01; 68(1):57-66. PubMed ID: 37898984
    [Abstract] [Full Text] [Related]

  • 20. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chrétien ML, Bastie JN, Brunotte F, Casasnovas RO.
    J Nucl Med; 2014 Apr 01; 55(4):569-73. PubMed ID: 24566003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.